INDEX

Chronic Obstructive Lung Disease is abbreviated as COLD throughout this index.

ACROLEIN
alpha$_1$-antitrypsin effect, 436
alveolar macrophage effects, 432
cilioinhibitory effect, 295
gas phase component, 294, 417

ADDICTION
cessation of smoking, relationship, 468, 481, 485

ADDITIVES
(*See also* **MENTHOL; PHENOL**)
low yield cigarettes, increasing use, 13, 352, 354

ADOLESCENTS
(*See also* **CHILDREN**)
increased cough in smokers, 6
prevalence of cough and amount smoked, 64
sex differences in prevalence of respiratory symptoms, 66
small airways dysfunction in smokers, 37, 427
smoking rates with smoking and nonsmoking parents, 506

ADVERTISING
(*See also* **MASS MEDIA**)
government regulation of tobacco advertising, 506–507, 514, 520, 527
promotion of cardiovascular risk reduction, 508
smoking cessation or reduction effects, 457

AGE DIFFERENCES
airflow obstruction incidence, 103
cessation rates in post-MI patients, 475
cessation success, 468
chronic airflow obstruction, prevalence, 78
chronic bronchitis, prevalence, 46–47
COLD mortality, 191–192, 197, 203–205

AGE DIFFERENCES—Contd.
cough and phlegm, prevalence, 48, 65–68
emphysema, severity in smokers and nonsmokers, 126, 241–242
initiation of smoking and COLD mortality, 209
lung pathology in smokers, 124–125, 231
mucociliary transport, 283
pulmonary function, 6
pulmonary function in children of smoking parents, 398
pulmonary function, rate of decline, 9, 137
reductions in smoking with community intervention studies, 511–512
small airways dysfunction, 9, 29–30, 32–35, 37–39, 136–137

AIR POLLUTION
(*See also* **PASSIVE SMOKING**)
airflow obstruction relationship, 105
bronchitis morbidity factor, 212
COLD mortality factor, 192
lung clearance effect, 424
particulates exposure compared with smoking, 417
workplace levels and pulmonary function, 31

ALCOHOL CONSUMPTION
abstinence in pregnancy, 462
airflow obstruction relationship, 105–106

ALLERGY
atopy and pulmonary function, 106
lung hypersensitivity and airflow obstruction, 104–105, 118
skin test reactivity and incidence of airflow obstruction, 103

Alpha$_1$-antiprotease *See* **ALPHA$_1$-ANTITRYPSIN**
ALPHA$_1$-ANTITRYPSIN
antiprotease activity, 262–264
deficiency in panacinar emphysema, 234–235
elastase inhibition, 8, 11, 301
genetic deficiency, 9–10, 83, 104, 118, 129–137, 261–262, 275
oxidants and decreased inhibitory capacity, 273–274, 435
papain elastolysis, inhibitor, 265
tar and nicotine content effect on elastase inhibition, 340
tobacco smoke effects, 434–437
Alpha$_1$-proteinase inhibitor *See* **ALPHA$_1$-ANTITRYPSIN**
ALVEOLAR MACROPHAGES
changes in smokers, 255–257, 259, 261, 278–279
changes induced by tobacco smoke, 431–434
emphysema pathogenesis, role, 268–270
increased numbers in smokers, 11, 270–271, 301
increased numbers with nitrogen dioxide, 276
lung clearance mechanisms, role, 423–424
neutrophil chemotaxis, role, 258
toxicity of cigarette smoke, 279–280
ALVEOLITIS
smoking relationship, 255
AMISH
COLD mortality, 213
AMMONIA
gas phase component, 294, 417
ANGINA
contraindication for nicotine chewing gum, 477
Antibodies *See* **IMMUNE SYSTEM**
ANTISMOKING CAMPAIGNS
(*See also* **SMOKING INTERVENTION STUDIES**)
smoking behavior, effect, 457
smoking cessation at prenatal clinics, effect, 462–463
ASBESTOS
cessation success in exposed shipyard workers, 482–483
ASTHMA
bronchoconstrictive effect of smoke inhalation in asthmatics, 428–429
children of smoking parents, 389, 392–393, 403
mortality in California physicians, 211
nonsmokers exposed to tobacco smoke, 403, 405–406
reversibility of airflow obstruction, 75
ATROPINE
cilioinhibitory effect, 295
AVERSIVE SMOKING
cessation effectiveness, 469

BACTERIA
clearance from respiratory tract, 281
macrophage bactericidal capacity in smokers and nonsmokers, 278–279
reduced resistance to infection in smoke-exposed animals, 280
BEHAVIOR MODIFICATION
physicians' efforts to get patients to quit, 455
social reinforcement in community intervention trials, 506
BIRTHWEIGHT
maternal smoking relationship, 461, 464–465
BRONCHIOLITIS
childhood, association with subsequent panacinar emphysema, 236
COLD, role in pathogenesis, 11
pathology, 223, 230–231
smoking relationship, 242, 255–256
BRONCHITIS
(*See also* **MUCUS HYPERSECRETION**)
abnormalities in regional gas exchange, 22
aerosol clearance effects, 292–293
childhood, association with panacinar emphysema, 236
children of smoking parents, 13, 393, 405
definition, 45–46, 224
excessive morbidity in Britain, 212
mortality and age of smoking initiation, 209–210

INDEX

BRONCHITIS—Contd.
mortality and depth of inhalation, 208
mortality and smoking habit, 201
mortality in physicians, 211
mucociliary dysfunction, 12, 283, 297–302
natural history, 115
particulate phase components, role, 426
pathology, 227, 229
prevalence, 46
smoking relationship, 48, 255

BRONCHOCONSTRICTION
dogs exposed to cigarette smoke, 429
induction by cigarette smoke, 428, 430
inhalation pattern relationship, 349–350
low yield cigarettes effect, 341

CADMIUM
induction of emphysematous lesions in animals, 276
tobacco smoke component, 426

CARBON DIOXIDE
gas phase component, 417

CARBON MONOXIDE
breath test to demonstrate smoking effects in pregnant women, 464
breath test to validate self-reported cessation, 460, 463
gas phase component, 417
increased alveolar epithelial permeability, role, 430
indoor air pollutant, 366, 383
low-tar and low-nicotine cigarettes, yields, 345–346

CARBOXYHEMOGLOBIN
asthmatics exposed to tobacco smoke, levels, 403
inhalation pattern relationship, 345, 349
measure of carbon monoxide absorption, 366, 383
nonsmokers exposed to tobacco smoke, levels, 384

CARCINOGENESIS
consequence of mucociliary dysfunction, 301

CASEIN
chemotaxis of polymorphonuclear leukocytes, effect, 433

CATALASE
reduction of smoke effects on alpha$_1$-protease inhibitor, 436

CERULOPLASMIN
prevention of alpha$_1$-antitrypsin oxidation, 274

CESSATION OF SMOKING
(*See also* **REDUCTION OF SMOKING**)
cardiopulmonary function improvement, 465
COLD incidence and progression effects, 7–8
COLD mortality relationship, 10, 210–211, 214
community intervention studies, 15, 503-528
cough and phlegm reduction, 9, 48, 137
emphysema morbidity and mortality, 126
emphysema severity in ex-smokers, 241–242
emphysematous changes, effect, 127–129
lung clearance effects, 430
mechanical properties of lungs, effect, 123
morbidity and mortality reduction, 465
mucociliary transport effects, 293, 300
parents, effect on children's asthma, 403
physicians, 456
pulmonary function effects, 9, 227, 232, 242
pulmonary function effects, rate of decline, 9, 116–118, 137
reasons given by ex-smokers, 457
respiratory symptoms in ex-smokers, 67
role of physicians, 14, 455–488
sex differences in pulmonary function effects, 104
small airways function effects, 11, 40–42, 44, 137

CHEST INFECTIONS
airflow obstruction, role in etiology, 83, 107

CHILDREN
(*See also* **ADOLESCENTS**)
influence on parental smoking cessation, 468

480-144 O - 85 - 19

CHILDREN—Contd.
pulmonary function effects of smoking, 398
respiratory illnesses and subsequent airflow obstruction, 104, 106, 118
respiratory infections and COLD susceptibility, 7
respiratory symptoms, parental smoking relationship, 13, 388–389, 392–393, 397–398, 402–403, 405
school-based prevention programs, 519–524
CHLORAMINE-T
inhibitory capacity of alpha$_1$-antitrypsin, effect, 273–274, 436
Chronic airflow obstruction *See* **PULMONARY FUNCTION**
CIGAR SMOKERS
COLD mortality, 10, 211–212, 214
cough and phlegm prevalence, 48
emphysema incidence at autopsy, 240
former cigarette smokers, 460
Cilia *See* **MUCOCILIARY TRANSPORT**
CORONARY HEART DISEASE
contraindication for nicotine chewing gum, 477
COTININE
nicotine exposure in nonsmokers, measure, 13, 383, 405
urinary levels in children of smoking mothers, 397
COUGH
(*See also* **MUCUS HYPERSECRETION**)
children of smoking parents, 388
contribution to pulmonary clearance, 300
increase in smokers, 6
low yield cigarettes effect, 336–339, 354
prevalence in smokers vs. nonsmokers, 9
tobacco smoke exposure as factor, 386
CREATININE
urinary levels in children of smoking mothers, 397
CROSS-CULTURAL STUDIES
COLD mortality, 10–11, 212–214
CYSTIC FIBROSIS
impairment of mucociliary transport, 283
submucosal gland enlargement, 225
DIABETES
contraindication for nicotine chewing gum, 477
EDUCATIONAL ATTAINMENT
cessation of smoking, relationship, 462, 468
ELASTASE
experimental induction of emphysema, 8, 122–123, 134, 266–270
increase in people deficient in alpha$_1$-antitrypsin, 262
increased activity in smokers, 271, 301
inhibition by alpha$_1$-antitrypsin, 301
inhibition by protease inhibitors, 434–435, 437
low yield cigarettes effects, 340
pathogenesis of COLD, role, 11
physiochemical conditions that modify kinetics, 272–273
proximity in elastin degradation, role, 272
release by macrophages and neutrophils, 257–258, 271–272, 301, 432–434
ELASTIN
chemoattractant for blood monocytes, 258
degradation by elastase, 8
degradation by elastase, role of proximity, 272
degradation by papain, 265
synthesis and repair, cigarette smoke effect, 14, 438–439
EMPHYSEMA
age of smoking initiation and mortality, 209–210
amount smoked and severity, 11, 137
animal models, 275–278, 433
bronchiolitis as precursor, 256
COLD disease process, 21
definition and characterization, 119–120
detection, 120
gas phase components, role, 426
irreversibility, 75

INDEX

EMPHYSEMA—Contd.
lung clearance mechanisms effect, 424
mechanical properties of lungs in etiology, 122–123
mortality in physicians, 211
oxidants in pathogenesis, 426–427
pathogenic mechanisms, 11–12, 261, 275–301, 431, 435, 437
pathology, 223, 226, 230–242
peripheral airway resistance, 22
protease-antiprotease imbalances in pathogenesis, 11, 262, 270–278, 301, 339–340
pulmonary function, 26, 121–122
quantification, 120–121
smoking relationship, 8, 10, 125–135, 255

ESOPHAGITIS
contraindication for nicotine chewing gum, 477

EXERCISE
cessation in post-MI patients, effect, 475
lung deposition of aerosols, effect, 421
promotion in community intervention studies, 508

EYES
irritation following acute exposure to tobacco smoke, 13, 386–387, 405

FAMILY
influence of support on smoking cessation, 457, 485, 506
recidivism prevention in post-MI patients, 475

FIBROBLASTS
membrane damage caused by tobacco smoke, 438

FIBROSIS
lung clearance mechanisms, effect, 424

FILTER CIGARETTES
(*See also* **LOW YIELD CIGARETTES**)
amount smoked and prevalence of mucus hypersecretion, 65
cilioinhibitory capacity, 287
filter use and cessation probability, 469
mucociliary transport effects, 296–297

FILTER CIGARETTES—Contd.
pulmonary function effects, 116

GENETIC FACTORS
alpha$_1$-antitrypsin deficiency, 9–10, 83, 104, 118, 129–137, 261–262, 275
development of airflow obstruction, 104, 106–107

GROUP COUNSELING
cessation rates in post-MI patients, effect, 475

HEADACHE
after acute exposure to tobacco smoke, 386

HEXAMETHONIUM
cilioinhibitory effect, 295

HISTAMINE
involvement in bronchoconstrictive response to smoking, 428
reactivity in smokers and nonsmokers, 430
release in animals exposed to tobacco smoke, 429

HYDROGEN CYANIDE
ciliotoxicity, 283, 295

HYDROGEN PEROXIDE
alpha$_1$-protease inhibition, effect, 436
enhanced production in alveolar macrophages in smokers, 432
inactivation of alpha$_1$-antitrypsin, 274

HYPERKINESIS
maternal smoking relationship, 461

HYPERTENSION
cardiovascular risk reduction program, factor, 515
contraindication for nicotine chewing gum, 477
pulmonary artery, association with chronic airflow obstruction, 232

HYPERTHYROIDISM
contraindication for nicotine chewing gum, 477

IMMUNE SYSTEM
ABH antigens and airflow obstruction, 105
COLD susceptibility, factor, 7
smoking effects, 12, 255, 279–281, 301

INFLUENZA
increased susceptibility in smokers, 12, 280, 301
Involuntary smoking *See* **PASSIVE SMOKING**
ISOPRENE
mucociliary transport effects, 295
ISOPROTERENOL
reversal of airways reactivity, 105

LACTATION
inhibition by maternal smoking, 461
LEAD
particulate phase component, 417
LEGISLATION
restrictions on smoking in public places, 507, 514, 520, 527
LOBELINE
nicotine substitute, 458
LOW YIELD CIGARETTES
(*See also* **FILTER CIGARETTES**)
additives, 13, 352–354
cessation success and tar yield, 461
COLD mortality, 198, 201, 203
COLD risk, 12–13, 336–341, 354
lung cancer mortality relationship, 339
mucociliary transport effects, 294
particulate concentrations and size, 418–419
research recommendations, 353
respiratory symptoms, 66
smoking behavior effects, 341–348, 354
tar yield and respiratory symptoms, 65
LUNG CANCER
aerosol deposition at bronchogenic carcinoma sites, 422
low yield cigarettes relationship, 339
mortality in smokers, 336
polonium deposition and site of bronchogenic carcinoma, 424
smoking behavior relationship, 333
smoking relationship, 255
LUNGS
cigarette-induced disease, pathology, 11
growth in children of smoking mothers, 398
localization of emphysematous lesions, 275
LUNGS—Contd.
pulmonary epithelial permeability and smoking, 430–431, 439
tissue repair, cigarette smoking effects, 437

Macrophages *See* **ALVEOLAR MACROPHAGES**
MARITAL STATUS
cessation of smoking, relationship, 468–469
MASS MEDIA
(*See also* **ADVERTISING**)
antismoking educational campaigns, 480
community intervention studies, 15, 505–506, 508–514, 523, 526, 528
televised smoking cessation classes, 519
MATERNAL SMOKING
(*See also* **PARENTAL SMOKING; PREGNANCY**)
fetal and childhood effects, 461
prenatal smoking and respiratory infections in children, 393
METHACHOLINE
responsiveness and airways reactivity, 105
responsiveness and smoking, 428–429
METHOL
mucociliary transport effects, 295
Minority groups *See* **RACIAL/ETHNIC DIFFERENCES**
MORBIDITY
bronchitis in Britain, 212
chronic airflow obstruction, 68–118
chronic mucus hypersecretion, 45–73
COLD prevalence and inhalation practices, 209
emphysema, 119–135
improvement following cessation of smoking, 465
small airways dysfunction, 22–44
smoking and COLD morbidity, 8–10
MORTALITY
cardiovascular diseases, declines related to risk factor reduction program, 515
cessation of smoking relationship, 465
COLD, airflow obstruction relationship, 339

MORTALITY—Contd.
COLD, mucus hypersecretion relationship, 339
COLD, smoking relationship, 8, 10–11, 189–214, 336
fetal and neonatal, maternal smoking effect, 461
myocardial infarction patients who quit smoking, 470
predictive effectiveness of FEV_1, 72
MUCOCILIARY TRANSPORT
chronic bronchitis, 297–301
filters, effect, 296–297
lung clearance of deposited particulates, 423–424
normal function, 283–286
smoke constituents, effect, 293–296, 426
tobacco smoke, effect, 12, 290–296, 301–302, 418, 431
MUCUS HYPERSECRETION
cigarette smoke effects, 11, 107, 292, 302
COLD disease process, 21
COLD mortality relationship, 339
cough and phlegm, relationship to airflow obstruction, 68–73
cough and phlegm, relationship to sex and age, 65–68
cough and phlegm, relationship to smoking, 47–48, 63–65
inhalation depth relationship, 349
low yield cigarettes, effect, 336–339, 354
measurement of cough and phlegm, 45–46
phlegm in smokers vs. nonsmokers, 9
prevalence and amount smoked, 137
prevalence of cough and phlegm, 46–47
MYELOPEROXIDAS
inactivation of $alpha_1$-antitrypsin, 274, 436–437
MYOCARDIAL INFARCTION
cessation of smoking in post-MI patients, 15, 470, 475–476, 480–481, 487
contraindication for nicotine chewing gum, 477
N-CHLORSUCCINIMIDE
reduction of activity of $alpha_1$-antitrypsin, 436
NEUTROPHILS
changes induced by tobacco smoke, 255–261, 432–434
chemotaxis inhibition by cigarette smoke, 269–270
decrease following elastase instillation, 266
elastase source, 257–258, 267–268, 271–272
increased numbers in smokers, 11, 256–257, 270–271, 301
increased numbers with nitrogen dioxide, 276
migration in response to macrophage chemotactic factor, 258
toxicity of cigarette smoke, 279–280
NICOTINE
$alpha_1$-protease inhibitor effect, 436
alveolar epithelial permeability effect, 430
blood levels with nicotine chewing gum, 476
bronchial reactivity effect in baboons, 430
bronchoconstriction effect, 428
chemokinetic factor for neutrophils, 258, 432–433
compensatory behavior in smokers of low nicotine cigarettes, 421
DNA synthesis effect, 280
indoor air pollutant, 366
machine-determined yields and actual intake, 335–336, 346–347
mucociliary transport effects, 295
nonsmokers exposed to tobacco smoke, levels, 383
particulate phase component, 417
reinforcer of smoking behavior, 13
saliva levels to validate cessation reports, 459
NICOTINE CHEWING GUM
cessation aid, 14, 460, 476–478, 487
NITRIC OXIDE
mucociliary transport effects, 295
NITROGEN DIOXIDE
effect on macrophages, 279
emphysematous lesions in animals, role in induction, 276
gas phase component, 294
mucociliary transport effects, 295

NITROGEN OXIDES
acute bronchospasm effects, 428
epithelial permeability effects, 430–431
gas phase component, 417
indoor air pollutant, 366
lung clearance mechanisms, toxic effects, 424
NITROSAMINES
indoor air pollutants, 366
Nonsmokers *See* **PASSIVE SMOKING**
NOSE
irritation following acute exposure to tobacco smoke, 386
NURSES
involvement in community intervention studies, 514

OCCUPATIONS
(*See also* **WORKPLACE**)
coal miners, 230, 234, 240
grain elevator workers, 31
industrial workers, 277
iron foundry workers, 42
physicians, 14–15, 194, 198, 206, 208, 210–211, 455–488, 511, 514, 527
shipyard workers, 482–483
steelworkers, 30, 43
textile workers, 225, 242
OZONE
lung clearance mechanisms, toxic effects, 424
preexposure and cigarette smoke effects in animals, 437

PAPAIN
emphysema pathogenesis, role, 265–266
PARENTAL SMOKING
(*See also* **MATERNAL SMOKING**)
children's encouragement to quit, effect, 519–520
influence on adolescent smoking rates, 506
pulmonary function in children, 397–398, 405
respiratory infections in children, 393, 397, 405
respiratory symptoms in children, 13, 388–389, 392, 403, 405
PARTICULATES
(*See also* **TARS, TOBACCO**)

PARTICULATES—Contd.
aerodynamic diameter, 418–420, 438
exposure measurement, 383
indoor air pollutants, 366
ingestion by pulmonary macrophages, 259
lung deposition, 420–422, 425, 438
lung retention, 423–424
PASSIVE SMOKING
acute airway response, 384, 386
children, respiratory infections related to parental smoking, 393, 397
children, subsequent susceptibility to COLD, 7
COLD risk effect, 13
deposition of particulates in lungs, 425
exposure measurement, 316, 383–384
patients with preexisting pulmonary disease, 403–405
prevalence of respiratory symptoms, 66
pulmonary function in children, parental smoking relationship, 397–402
pulmonary function relationship, 402–403
sidestream vs. mainstream smoke, 365–366
symptomatic responses, 386–392
PEPSIN
emphysema induction in experimental animals, 123
PEPTIC ULCER
contraindication for nicotine chewing gum, 477
PEROXIDASE
transfer across tracheal epithelium, 431
PERSONALITY
cessation of smoking factor, 469, 481–482, 485
PHENOL
mucociliary transport effects, 295–296
PHENYLMETHYLOXADIOZOLE
anticiliotoxic effects, 296
PHENYLVINYLOXADIOZOLE
anticiliotoxic effects, 296

INDEX

Phlegm *See* **MUCUS HYPERSECRETION**
PHYSICIANS
cessation of smoking and COLD mortality, 210–211
COLD mortality, 194, 198, 206, 208
involvement in community intervention studies, 511, 514, 527
smoking cessation in patients, role, 14–15, 455–488
smoking prevalence, 14, 456
PIPE SMOKERS
COLD mortality, 10, 211–212, 214
cough and phlegm prevalence, 48
emphysema incidence at autopsy, 240
former cigarette smokers, 460
PNEUMOCONIOSIS
pathology, 225, 234
PNEUMONIA
children of smoking parents, 13, 393, 405
POLONIUM
deposition at site of bronchogenic carcinoma, 424
particulate phase component, 417
POLYCYCLIC AROMATIC HYDROCARBONS
fibroblast membrane effects, 438
Polymorphonuclear leukocytes *See* **NEUTROPHILS**
PREGNANCY
(*See also* **MATERNAL SMOKING**)
antibody production in pregnant smokers, 280
cessation of smoking, 14, 479–480, 487
motivation for quitting, 484
physician intervention and cessation of smoking, 461–465
PREVENTION OF SMOKING
community intervention studies, 15, 520–524
PROTEASE-ANTIPROTEASE IMBALANCE
alpha$_1$-antitrypsin deficiency, 130
effect of oxidants, 275
emphysema pathogenesis, 11, 262, 270–278, 301, 339–340
smoke exposure effect, 277–278
PULMONARY FUNCTION
airway lesions relationship, 227, 229
asthma patients, 13, 403, 405–406
PULMONARY FUNCTION—Contd.
children of smoking parents, 13, 393, 397–398, 405
chronic airflow obstruction, 42–44, 68–118, 223–232
cigarette smoke effects, 6, 9, 191, 427–430, 438
emphysema, 121–122
expiratory airflow obstruction as COLD disease process, 21
inflammation and small airways dysfunction, 11
inhalation depth relationship, 349
low yield cigarettes relationship, 337–338, 354
occupational exposure relationship, 107
passive smoking effects, 13, 384–386, 402–403, 405
people deficient in alpha$_1$-antitrypsin, 262
small airways dysfunction, 22–44, 136–137, 227
RACIAL/ETHNIC DIFFERENCES
cessation of smoking during pregnancy, 462
chronic airflow obstruction, prevalence, 78
COLD mortality, 11, 191, 214
COLD risk, 212–213
serum concentrations of alpha$_1$-antitrypsin, 263
smoking prevalence trends, 504
RECIDIVISM
post-MI patients, environmental factors, 475
pregnant smokers, before end of pregnancy, 463
REDUCTION OF SMOKING
(*See also* **CESSATION OF SMOKING**)
physician intervention, effectiveness, 458–459
pregnant women, 463–465
psychologist's advice, effectiveness, 468–469
RESPIRATORY SYNCYTIAL VIRUS INFECTION
children of smoking mothers, 393, 397
SEX DIFFERENCES
airflow obstruction prevalence, 78, 83

SEX DIFFERENCES—Contd.
cessation of smoking, 468
cessation rates in post-MI patients, 475
cholesterol reduction, 512
chronic bronchitis mortality, 210
chronic bronchitis prevalence, 46–47
COLD mortality, 10, 189, 192, 203–207, 213–214
community intervention effectiveness, 511, 514
cough and phlegm prevalence, 48, 65–68
emphysema incidence at autopsy, 240–241
emphysema severity at autopsy, 241–242
particulates deposition, 423
preventive effect of school-based smoking interventions, 522
pulmonary function after passive smoking, 384–386
reduction of smoking following physician intervention, 458–459
small airways dysfunction, 9, 28, 37–40, 137
smoking patterns and pulmonary function, 32–33, 35, 104
smoking prevalence, 504
Small airways disease *See* **PULMONARY FUNCTION**
SMOKING BEHAVIOR
cigarette yields, effect, 13, 64, 334–335
inhalation pattern and cessation probability, 469
inhalation pattern and COLD mortality, 208–209, 214
inhalation pattern and COLD susceptibility, 7, 348–352, 354
low yield cigarettes relationship, 12–13, 341–348, 354
lung deposition of particulates, effect, 420–423, 425
lung injury relationship, 341
SMOKING INTERVENTION STUDIES
(*See also* **ANTISMOKING CAMPAIGNS**)
cessation and prevention effects, 15
community cessation studies, 504–505, 507–520, 528
SMOKING INTERVENTION STUDIES
community prevention studies, 520–524, 528
methodological issues, 524–526, 528
research needs, 526–528
theoretical basis, 505–507
SMOKING-MACHINES
comparability to actual smoking behavior, 12, 64, 333–336, 341, 354, 420–421
SMOKING PATTERNS
age of initiation and COLD mortality, 209–210
alveolar macrophage changes and amount smoked, 256
cessation probability and amount smoked, 459, 469, 481
COLD morbidity relationship, 9
COLD mortality and amount smoked, 10, 198, 201, 203, 205–208, 210–211, 213–214
COLD severity relationship, 336
cough and phlegm prevalence, 9, 47–48, 137
determinants of airflow obstruction, 92, 103–104
emphysema at autopsy and amount smoked, 240–241
emphysema severity, 10, 137
emphysematous changes and amount smoked, 126–127
mucus hypersecretion and amount smoked, 63–65
pulmonary function and amount smoked, 6–7, 9, 69, 115, 117, 131, 137
respiratory symptoms prevalence, 73
small airways dysfunction and amount smoked, 32–35, 39, 43, 136–137
SMOKING PREVALENCE
physicians, 456, 487
trends in various demographic groups, 503–504
SOCIOECONOMIC STATUS
cessation of smoking, relationship, 468–469
pulmonary function relationship, 108
reduction in tobacco consumption in higher income groups, 503
smoking prevalence, 525–526, 528
trend toward reduced smoking, 15

INDEX

Sputum *See* **MUCUS HYPERSECRETION**
STRESS
cessation success relationship, 481–482
chronic smoking relationship, 527
management training to maintain nonsmoking, 509
SUPEROXIDE DISMUTASE
activity depression by tobacco smoke, 434
reduction of smoke effects on alpha$_1$-protease inhibitor, 436
SUPEROXIDE RADICALS
alpha$_1$-protease inhibitor activity, effect, 436
generation by alveolar macrophages in smokers, 259, 432
release from neutrophils in smokers, 433

TARS, TOBACCO
(*See also* **PARTICULATES**)
ciliotoxic effect, 295
cough and phlegm production relationship, 337
exposure in nonsmokers, 384
mucus hypersecretion relationship 12, 339
pulmonary function relationship, 338
respiratory symptoms effect, 65
smoking behavior relationship, 13, 347–348, 354
TAXES
increases as part of community intervention trials, 514
TAXES—Contd.
revenues contributed by tobacco industry, 503
smoking deterrent effectiveness, 457, 507, 520, 527
THIOCYANATE
plasma levels to validate self-reports of cessation, 512
saliva levels to validate self-reports of cessation, 464
serum levels to validate self-reports of cessation, 508–509, 511, 513, 518, 521–522
TOBACCO SMOKE
aerosol characterization, 417–420, 438
deposition and toxicity, 14
mainstream vs. sidestream smoke, 365–366
toxicology, 426–439
TRACHEA
epithelial permeability in smoke-exposed animals, 430–431

WHEEZING
children of smoking parents, 388–389, 392–393
WOOD SMOKE
airflow obstruction, etiologic factor, 83
WORKPLACE
(*See also* **OCCUPATIONS**)
air pollution and pulmonary function, 31
smoking prohibitions and cessation, 457